Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05017298Phase 2Not Yet Recruiting

Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells

Role: lead

NCT04855955Unknown

Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

Role: lead

NCT04448106Phase 2Not Yet Recruiting

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis

Role: lead

NCT04170426Phase 1Not Yet Recruiting

Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis

Role: lead

NCT04428801Phase 2Not Yet Recruiting

Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19

Role: lead

All 5 trials loaded